Moshe Shashar1, Naomi Nacasch2,3, Ayelet Grupper3,4, Sydney Benchetrit2,3, Tamar Halperin5, Daniel Erez3,6, Ilan Rozenberg2,3, Pnina Shitrit3,7, Yaron Sela8, Ori Wand3,9, Keren Cohen-Hagai2,3. 1. Department of Nephrology and Hypertension, Laniado Hospital, Netanya, Israel. 2. Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Department of Nephrology and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 5. Laboratory for HIV Diagnosis, The HIV Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 6. Department of Internal Medicine D, Meir Medical Center, Kfar Saba, Israel. 7. Infection Control Unit, Meir Medical Center, Kfar Saba, Israel. 8. Interdisciplinary Center (IDC), Reichman University, Herzliya, Israel. 9. Department of Pulmonology, Meir Medical Center, Kfar Saba, Israel.
Abstract
INTRODUCTION: Coronavirus disease is associated with increased morbidity and mortality in maintenance hemodialysis (MHD) patients. Recent breakthrough infection in vaccinated people has led some authorities to recommend a booster dose for patients fully vaccinated 5-8 months ago. We aimed to assess the humoral response of MHD patients following a booster dose with the BNT162b2 vaccine. METHODS: The study included 102 MHD patients vaccinated with 2 doses of the BNT162b2 (Pfizer-BioNTech) vaccine. A third dose (booster) was recommended to all MHD patients in our center and was given to those who opted to receive it, resulting in a booster group and a control group that did not receive the booster. Previous exposure was excluded by testing for the presence of the anti-nucleocapsid antibody (SARS-CoV-2) or positive PCR. We assessed the humoral response before and after the booster dose. RESULTS: Of 66 patients in the booster group, 65 patients (98.5%) developed a positive antibody response, from 472.7 ± 749.5 to 16,336.8 ± 15,397.3, as compared to a sustained decrease in the control group (695.7 ± 642.7 to 383.6 ± 298.6), p < 0.0001. No significant adverse effects were reported. Prior antibody titers were positively correlated to IgG levels following the booster dose. There was a significant association between malnutrition-inflammation markers and the humoral response. CONCLUSIONS: Almost all MHD patients developed a substantial humoral response following the booster dose, which was significantly higher than levels reported for MHD patients following administration of 2 doses alone. Further studies and observations are needed to determine the exact timing and dosing schedule.
INTRODUCTION: Coronavirus disease is associated with increased morbidity and mortality in maintenance hemodialysis (MHD) patients. Recent breakthrough infection in vaccinated people has led some authorities to recommend a booster dose for patients fully vaccinated 5-8 months ago. We aimed to assess the humoral response of MHD patients following a booster dose with the BNT162b2 vaccine. METHODS: The study included 102 MHD patients vaccinated with 2 doses of the BNT162b2 (Pfizer-BioNTech) vaccine. A third dose (booster) was recommended to all MHD patients in our center and was given to those who opted to receive it, resulting in a booster group and a control group that did not receive the booster. Previous exposure was excluded by testing for the presence of the anti-nucleocapsid antibody (SARS-CoV-2) or positive PCR. We assessed the humoral response before and after the booster dose. RESULTS: Of 66 patients in the booster group, 65 patients (98.5%) developed a positive antibody response, from 472.7 ± 749.5 to 16,336.8 ± 15,397.3, as compared to a sustained decrease in the control group (695.7 ± 642.7 to 383.6 ± 298.6), p < 0.0001. No significant adverse effects were reported. Prior antibody titers were positively correlated to IgG levels following the booster dose. There was a significant association between malnutrition-inflammation markers and the humoral response. CONCLUSIONS: Almost all MHD patients developed a substantial humoral response following the booster dose, which was significantly higher than levels reported for MHD patients following administration of 2 doses alone. Further studies and observations are needed to determine the exact timing and dosing schedule.
Authors: Leena Taji; Doneal Thomas; Matthew J Oliver; Jane Ip; Yiwen Tang; Angie Yeung; Rebecca Cooper; Andrew A House; Phil McFarlane; Peter G Blake Journal: CMAJ Date: 2021-02-04 Impact factor: 8.262
Authors: Noam Barda; Noa Dagan; Cyrille Cohen; Miguel A Hernán; Marc Lipsitch; Isaac S Kohane; Ben Y Reis; Ran D Balicer Journal: Lancet Date: 2021-10-29 Impact factor: 79.321
Authors: Nassim Kamar; Florence Abravanel; Olivier Marion; Chloé Couat; Jacques Izopet; Arnaud Del Bello Journal: N Engl J Med Date: 2021-06-23 Impact factor: 91.245
Authors: Julian Stumpf; Torsten Siepmann; Tom Lindner; Claudia Karger; Jörg Schwöbel; Leona Anders; Robert Faulhaber-Walter; Jens Schewe; Heike Martin; Holger Schirutschke; Kerstin Barnett; Jan Hüther; Petra Müller; Torsten Langer; Thilo Pluntke; Kirsten Anding-Rost; Frank Meistring; Thomas Stehr; Annegret Pietzonka; Katja Escher; Simon Cerny; Hansjörg Rothe; Frank Pistrosch; Harald Seidel; Alexander Paliege; Joachim Beige; Ingolf Bast; Anne Steglich; Florian Gembardt; Friederike Kessel; Hannah Kröger; Patrick Arndt; Jan Sradnick; Kerstin Frank; Anna Klimova; René Mauer; Xina Grählert; Moritz Anft; Arturo Blazquez-Navarro; Timm H Westhoff; Ulrik Stervbo; Torsten Tonn; Nina Babel; Christian Hugo Journal: Lancet Reg Health Eur Date: 2021-07-23
Authors: Frank-Peter Tillmann; Lars Figiel; Johannes Ricken; Hermann Still; Christoph Korte; Grete Plaßmann; Ana Harth; Achim Jörres; Philipp von Landenberg Journal: J Clin Med Date: 2022-06-02 Impact factor: 4.964